
@article{holbeckNationalCancerInstitute2017,
  title = {The {{National Cancer Institute ALMANAC}}: {{A Comprehensive Screening Resource}} for the {{Detection}} of {{Anticancer Drug Pairs}} with {{Enhanced Therapeutic Activity}}},
  shorttitle = {The {{National Cancer Institute ALMANAC}}},
  author = {Holbeck, Susan L. and Camalier, Richard and Crowell, James A. and Govindharajulu, Jeevan Prasaad and Hollingshead, Melinda and Anderson, Lawrence W. and Polley, Eric and Rubinstein, Larry and Srivastava, Apurva and Wilsker, Deborah and Collins, Jerry M. and Doroshow, James H.},
  year = {2017},
  month = jul,
  journal = {Cancer Research},
  volume = {77},
  number = {13},
  pages = {3564--3576},
  publisher = {{American Association for Cancer Research}},
  issn = {0008-5472, 1538-7445},
  doi = {10.1158/0008-5472.CAN-17-0489},
  abstract = {To date, over 100 small-molecule oncology drugs have been approved by the FDA. Because of the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations. Therefore, new combination strategies to overcome drug resistance in patients with advanced cancer are needed. In this study, we performed a systematic evaluation of the therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines (NCI-60) to uncover combinations with greater than additive growth-inhibitory activity. Screening results were compiled into a database, termed the NCI-ALMANAC (A Large Matrix of Anti-Neoplastic Agent Combinations), publicly available at https://dtp.cancer.gov/ncialmanac. Subsequent in vivo experiments in mouse xenograft models of human cancer confirmed combinations with greater than single-agent efficacy. Concomitant detection of mechanistic biomarkers for these combinations in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabine with bortezomib and nilotinib with paclitaxel in patients with advanced cancer. Consequently, the hypothesis-generating NCI-ALMANAC web-based resource has demonstrated value in identifying promising combinations of approved drugs with potent anticancer activity for further mechanistic study and translation to clinical trials. Cancer Res; 77(13); 3564\textendash 76. \textcopyright 2017 AACR.},
  chapter = {Therapeutics, Targets, and Chemical Biology},
  copyright = {\textcopyright 2017 American Association for Cancer Research.},
  langid = {english},
  pmid = {28446463},
  file = {C\:\\Users\\chris\\OneDrive\\Zotero\\Holbeck et al. - 2017 - The National Cancer Institute ALMANAC A Comprehen.pdf;C\:\\Users\\chris\\Zotero\\storage\\XISG56HY\\3564.html}
}

@article{manemModelingCellularResponse2019,
  title = {Modeling {{Cellular Response}} in {{Large-Scale Radiogenomic Databases}} to {{Advance Precision Radiotherapy}}},
  author = {Manem, Venkata SK. and Lambie, Meghan and Smith, Ian and Smirnov, Petr and Kofia, Victor and Freeman, Mark and Koritzinsky, Marianne and Abazeed, Mohamed E. and {Haibe-Kains}, Benjamin and Bratman, Scott V.},
  year = {2019},
  month = dec,
  journal = {Cancer Research},
  volume = {79},
  number = {24},
  pages = {6227--6237},
  issn = {0008-5472},
  doi = {10.1158/0008-5472.CAN-19-0179},
  abstract = {Radiotherapy is integral to the care of a majority of patients with cancer. Despite differences in tumor responses to radiation (radioresponse), dose prescriptions are not currently tailored to individual patients. Recent large-scale cancer cell line databases hold the promise of unravelling the complex molecular arrangements underlying cellular response to radiation, which is critical for novel predictive biomarker discovery. Here, we present RadioGx, a computational platform for integrative analyses of radioresponse using radiogenomic databases. We fit the dose\textendash response data within RadioGx to the linear-quadratic model. The imputed survival across a range of dose levels (AUC) was a robust radioresponse indicator that correlated with biological processes known to underpin the cellular response to radiation. Using AUC as a metric for further investigations, we found that radiation sensitivity was significantly associated with disruptive mutations in genes related to nonhomologous end joining. Next, by simulating the effects of different oxygen levels, we identified putative genes that may influence radioresponse specifically under hypoxic conditions. Furthermore, using transcriptomic data, we found evidence for tissue-specific determinants of radioresponse, suggesting that tumor type could influence the validity of putative predictive biomarkers of radioresponse. Finally, integrating radioresponse with drug response data, we found that drug classes impacting the cytoskeleton, DNA replication, and mitosis display similar therapeutic effects to ionizing radiation on cancer cell lines. In summary, RadioGx provides a unique computational toolbox for hypothesis generation to advance preclinical research for radiation oncology and precision medicine.The RadioGx computational platform enables integrative analyses of cellular response to radiation with drug responses and genome-wide molecular data.},
  file = {C\:\\Users\\chris\\OneDrive\\Zotero\\Manem et al_2019_Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance.pdf;C\:\\Users\\chris\\Zotero\\storage\\VETDWPIZ\\Modeling-Cellular-Response-in-Large-Scale.html}
}

@article{nairToxicoDBIntegratedDatabase2020,
  title = {{{ToxicoDB}}: An Integrated Database to Mine and Visualize Large-Scale Toxicogenomic Datasets},
  shorttitle = {{{ToxicoDB}}},
  author = {Nair, Sisira Kadambat and Eeles, Christopher and Ho, Chantal and Beri, Gangesh and Yoo, Esther and Tkachuk, Denis and Tang, Amy and Nijrabi, Parwaiz and Smirnov, Petr and Seo, Heewon and Jennen, Danyel and {Haibe-Kains}, Benjamin},
  year = {2020},
  month = jul,
  journal = {Nucleic Acids Research},
  volume = {48},
  number = {W1},
  pages = {W455-W462},
  issn = {0305-1048},
  doi = {10.1093/nar/gkaa390},
  abstract = {In the past few decades, major initiatives have been launched around the world to address chemical safety testing. These efforts aim to innovate and improve the efficacy of existing methods with the long-term goal of developing new risk assessment paradigms. The transcriptomic and toxicological profiling of mammalian cells has resulted in the creation of multiple toxicogenomic datasets and corresponding tools for analysis. To enable easy access and analysis of these valuable toxicogenomic data, we have developed ToxicoDB (toxicodb.ca), a free and open cloud-based platform integrating data from large in vitro toxicogenomic studies, including gene expression profiles of primary human and rat hepatocytes treated with 231 potential toxicants. To efficiently mine these complex toxicogenomic data, ToxicoDB provides users with harmonized chemical annotations, time- and dose-dependent plots of compounds across datasets, as well as the toxicity-related pathway analysis. The data in ToxicoDB have been generated using our open-source R package, ToxicoGx (github.com/bhklab/ToxicoGx). Altogether, ToxicoDB provides a streamlined process for mining highly organized, curated, and accessible toxicogenomic data that can be ultimately applied to preclinical toxicity studies and further our understanding of adverse outcomes.},
  copyright = {All rights reserved},
  file = {C\:\\Users\\chris\\OneDrive\\Zotero\\Nair et al. - 2020 - ToxicoDB an integrated database to mine and visua.pdf}
}

@article{seoSYNERGxDBIntegrativePharmacogenomic2020,
  title = {{{SYNERGxDB}}: An Integrative Pharmacogenomic Portal to Identify Synergistic Drug Combinations for Precision Oncology},
  shorttitle = {{{SYNERGxDB}}},
  author = {Seo, Heewon and Tkachuk, Denis and Ho, Chantal and Mammoliti, Anthony and Rezaie, Aria and Madani~Tonekaboni, Seyed~Ali and {Haibe-Kains}, Benjamin},
  year = {2020},
  month = jul,
  journal = {Nucleic Acids Research},
  volume = {48},
  number = {W1},
  pages = {W494-W501},
  issn = {0305-1048},
  doi = {10.1093/nar/gkaa421},
  abstract = {Drug-combination data portals have recently been introduced to mine huge amounts of pharmacological data with the aim of improving current chemotherapy strategies. However, these portals have only been investigated for isolated datasets, and molecular profiles of cancer cell lines are lacking. Here we developed a cloud-based pharmacogenomics portal called SYNERGxDB (http://SYNERGxDB.ca/) that integrates multiple high-throughput drug-combination studies with molecular and pharmacological profiles of a large panel of cancer cell lines. This portal enables the identification of synergistic drug combinations through harmonization and unified computational analysis. We integrated nine of the largest drug combination datasets from both academic groups and pharmaceutical companies, resulting in 22 507 unique drug combinations (1977 unique compounds) screened against 151 cancer cell lines. This data compendium includes metabolomics, gene expression, copy number and mutation profiles of the cancer cell lines. In addition, SYNERGxDB provides analytical tools to discover effective therapeutic combinations and predictive biomarkers across cancer, including specific types. Combining molecular and pharmacological profiles, we systematically explored the large space of univariate predictors of drug synergism. SYNERGxDB constitutes a comprehensive resource that opens new avenues of research for exploring the mechanism of action for drug synergy with the potential of identifying new treatment strategies for cancer patients.},
  file = {C\:\\Users\\chris\\OneDrive\\Zotero\\Seo et al. - 2020 - SYNERGxDB an integrative pharmacogenomic portal t.pdf;C\:\\Users\\chris\\Zotero\\storage\\Y8RL27C5\\5842189.html}
}

@article{shoemakerNCI60HumanTumour2006,
  title = {The {{NCI60}} Human Tumour Cell Line Anticancer Drug Screen},
  author = {Shoemaker, Robert H.},
  year = {2006},
  month = oct,
  journal = {Nature Reviews Cancer},
  volume = {6},
  number = {10},
  pages = {813--823},
  publisher = {{Nature Publishing Group}},
  issn = {1474-1768},
  doi = {10.1038/nrc1951},
  abstract = {The US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen (NCI60) was developed nearly 20 years ago, and is a valuable source of information about anticancer drug leads and mechanisms of growth inhibition.},
  langid = {english},
  keywords = {Biomedicine,Cancer Research,general},
  annotation = {Bandiera\_abtest: a Cg\_type: Nature Research Journals Primary\_atype: Reviews},
  file = {C\:\\Users\\chris\\Zotero\\storage\\D4AZP4QJ\\nrc1951.html}
}

@article{smirnovPharmacoGxPackageAnalysis2016,
  title = {{{PharmacoGx}}: An {{R}} Package for Analysis of Large Pharmacogenomic Datasets},
  shorttitle = {{{PharmacoGx}}},
  author = {Smirnov, Petr and Safikhani, Zhaleh and {El-Hachem}, Nehme and Wang, Dong and She, Adrian and Olsen, Catharina and Freeman, Mark and Selby, Heather and Gendoo, Deena M. A. and Grossmann, Patrick and Beck, Andrew H. and Aerts, Hugo J. W. L. and Lupien, Mathieu and Goldenberg, Anna and {Haibe-Kains}, Benjamin},
  year = {2016},
  month = apr,
  journal = {Bioinformatics (Oxford, England)},
  volume = {32},
  number = {8},
  pages = {1244--1246},
  issn = {1367-4811},
  doi = {10.1093/bioinformatics/btv723},
  abstract = {Pharmacogenomics holds great promise for the development of biomarkers of drug response and the design of new therapeutic options, which are key challenges in precision medicine. However, such data are scattered and lack standards for efficient access and analysis, consequently preventing the realization of the full potential of pharmacogenomics. To address these issues, we implemented PharmacoGx, an easy-to-use, open source package for integrative analysis of multiple pharmacogenomic datasets. We demonstrate the utility of our package in comparing large drug sensitivity datasets, such as the Genomics of Drug Sensitivity in Cancer and the Cancer Cell Line Encyclopedia. Moreover, we show how to use our package to easily perform Connectivity Map analysis. With increasing availability of drug-related data, our package will open new avenues of research for meta-analysis of pharmacogenomic data. AVAILABILITY AND IMPLEMENTATION: PharmacoGx is implemented in R and can be easily installed on any system. The package is available from CRAN and its source code is available from GitHub. CONTACT: bhaibeka@uhnresearch.ca or benjamin.haibe.kains@utoronto.ca SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.},
  langid = {english},
  pmid = {26656004},
  keywords = {Genomics,Humans,Neoplasms,Pharmacogenetics,Programming Languages,Software},
  file = {C\:\\Users\\chris\\OneDrive\\Zotero\\Smirnov et al. - 2016 - PharmacoGx an R package for analysis of large pha.pdf}
}

@article{yadavSearchingDrugSynergy2015,
  title = {Searching for {{Drug Synergy}} in {{Complex Dose}}\textendash{{Response Landscapes Using}} an {{Interaction Potency Model}}},
  author = {Yadav, Bhagwan and Wennerberg, Krister and Aittokallio, Tero and Tang, Jing},
  year = {2015},
  month = jan,
  journal = {Computational and Structural Biotechnology Journal},
  volume = {13},
  pages = {504--513},
  issn = {2001-0370},
  doi = {10.1016/j.csbj.2015.09.001},
  abstract = {Rational design of multi-targeted drug combinations is a promising strategy to tackle the drug resistance problem for many complex disorders. A drug combination is usually classified as synergistic or antagonistic, depending on the deviation of the observed combination response from the expected effect calculated based on a reference model of non-interaction. The existing reference models were proposed originally for low-throughput drug combination experiments, which make the model assumptions often incompatible with the complex drug interaction patterns across various dose pairs that are typically observed in large-scale dose\textendash response matrix experiments. To address these limitations, we proposed a novel reference model, named zero interaction potency (ZIP), which captures the drug interaction relationships by comparing the change in the potency of the dose\textendash response curves between individual drugs and their combinations. We utilized a delta score to quantify the deviation from the expectation of zero interaction, and proved that a delta score value of zero implies both probabilistic independence and dose additivity. Using data from a large-scale anticancer drug combination experiment, we demonstrated empirically how the ZIP scoring approach captures the experimentally confirmed drug synergy while keeping the false positive rate at a low level. Further, rather than relying on a single parameter to assess drug interaction, we proposed the use of an interaction landscape over the full dose\textendash response matrix to identify and quantify synergistic and antagonistic dose regions. The interaction landscape offers an increased power to differentiate between various classes of drug combinations, and may therefore provide an improved means for understanding their mechanisms of action toward clinical translation.},
  langid = {english},
  keywords = {ðŸ”¥,bliss,combination index,Doseâ€“response matrix,drug antagonism,Drug combination scoring,drug combinations,drug synergy,high single agent,High-throughput screening,Interaction landscape,loewe},
  file = {C\:\\Users\\chris\\OneDrive\\Zotero\\Yadav et al_2015_Searching for Drug Synergy in Complex Doseâ€“Response Landscapes Using an.pdf;C\:\\Users\\chris\\Zotero\\storage\\NBGZMIN7\\S2001037015000422.html}
}


